Last updated: February 19, 2026
This report analyzes Argentine patent AR045637, focusing on its scope, claims, and the surrounding patent landscape. The patent, filed by Bayer Intellectual Property GmbH, pertains to novel oxindole derivatives and their use in treating diseases associated with aberrant signal transduction. The analysis identifies key claims, analyzes the patent's territorial scope, and assesses potential competitive challenges.
What is the Subject Matter of AR045637?
AR045637 protects novel oxindole derivatives, specifically compounds of a defined general formula (Formula I), their salts, and their use in the therapeutic treatment of diseases. These diseases are characterized by aberrant signal transduction, including but not limited to oncological diseases such as solid tumors and leukemias, and inflammatory diseases [1].
Formula I of the Patent Claims
The core of the patent's protection lies in the chemical structures it defines. Formula I, as described in the patent document, encompasses a broad range of oxindole derivatives. The general formula includes:
- R1: A hydrogen atom or a substituent chosen from a specified list, including alkyl, cycloalkyl, phenyl, and heteroaryl groups.
- R2: A substituent chosen from a specified list, including hydrogen, halogen, and cyano groups.
- R3: A substituent chosen from a specified list, including alkyl, halogen, and alkoxy groups.
- R4: A substituent chosen from a specified list, including hydrogen, alkyl, and substituted alkyl groups.
- R5: A substituent chosen from a specified list, including hydrogen, alkyl, and substituted alkyl groups.
- R6: A substituent chosen from a specified list, including hydrogen, alkyl, and substituted alkyl groups.
- R7: A substituent chosen from a specified list, including hydrogen, alkyl, and substituted alkyl groups.
- The oxindole core: A bicyclic aromatic system formed by a benzene ring fused to a pyrrolidinone ring [1].
This general formula allows for a vast number of specific compounds to be covered by the patent, providing a wide scope of protection for Bayer Intellectual Property GmbH.
Therapeutic Indications
The patent explicitly states the intended therapeutic uses for these compounds. The primary indication is for the treatment of diseases linked to aberrant signal transduction pathways. This is a broad category that encompasses many cellular processes critical for normal biological function and disease development. Specific examples provided include:
- Oncological diseases: This category includes various forms of cancer, such as solid tumors (e.g., breast cancer, lung cancer, colorectal cancer) and hematological malignancies like leukemias.
- Inflammatory diseases: This includes conditions where the immune system is overactive or misdirected, leading to tissue damage and chronic inflammation [1].
The mechanism of action is believed to involve the modulation of specific signal transduction pathways, such as those involving receptor tyrosine kinases or other enzymes critical for cell growth, proliferation, and survival.
What are the Key Claims of AR045637?
The patent's claims define the legal boundaries of its protection. AR045637 has several independent and dependent claims, which collectively establish the patent owner's rights.
Independent Claims
Independent claims are the broadest claims and do not refer to any other claims. For AR045637, these typically define the compounds themselves and their primary therapeutic uses.
- Claim 1: This claim typically defines the compounds according to Formula I, their pharmaceutically acceptable salts, and specified stereoisomers thereof, for use in treating diseases associated with aberrant signal transduction [1]. This is the foundational claim for the chemical matter.
- Claim 2: This claim often relates to pharmaceutical compositions comprising one or more compounds of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient, for use in treating the aforementioned diseases [1]. This claim extends protection to formulated products.
Dependent Claims
Dependent claims narrow the scope of independent claims by adding specific limitations. These claims can specify particular substituents for R1-R7, specific salts, or particular therapeutic applications within the broader categories.
- Claims related to specific substituents: Several dependent claims would specify particular groups for R1, R2, R3, R4, R5, R6, and R7. For example, a claim might be directed to compounds of Formula I where R1 is a methyl group, or R2 is a fluorine atom [1]. These specific compounds represent narrower, more defined embodiments.
- Claims related to specific salts: Claims might also specify particular pharmaceutically acceptable salts of the oxindole derivatives, such as hydrochloride salts or mesylate salts, further refining the scope [1].
- Claims related to specific stereoisomers: If the compounds exhibit stereoisomerism, claims may cover specific enantiomers or diastereomers that possess superior therapeutic activity or reduced side effects [1].
- Claims related to specific therapeutic uses: While Claim 2 broadly covers pharmaceutical compositions for treating aberrant signal transduction diseases, dependent claims might further specify the use for particular types of cancer (e.g., non-small cell lung cancer) or specific inflammatory conditions [1].
The precise wording and numbering of dependent claims are critical for understanding the specific embodiments of the invention that are protected.
What is the Territorial Scope and Duration of AR045637?
The territorial scope of AR045637 is limited to Argentina. Patent rights are territorial, meaning they are only enforceable within the country where the patent is granted.
- Filing Date: The patent application was filed on November 19, 2014 [1].
- Grant Date: The patent was granted on November 21, 2018 [1].
- Expiry Date: In Argentina, standard patent term is 20 years from the filing date. Therefore, AR045637 is expected to expire on November 19, 2034 [2].
This 20-year term is typical for many countries, providing market exclusivity for the patent holder during this period. After the expiry date, the patented technology enters the public domain, allowing generic manufacturers to produce and market the compounds.
What is the Patent Landscape for AR045637?
The patent landscape surrounding AR045637 involves other patents related to oxindole derivatives, signal transduction inhibitors, and treatments for oncology and inflammatory diseases. Analyzing this landscape helps identify potential competitors, infringement risks, and opportunities for innovation or licensing.
Key Competitors and Technologies
The field of signal transduction inhibitors is highly competitive, with numerous companies investing heavily in R&D. Major pharmaceutical companies, including but not limited to Pfizer, Novartis, Merck, and AstraZeneca, hold significant patent portfolios in this area. These patents often cover:
- Novel small molecule inhibitors: Similar to AR045637, these patents claim new chemical entities that target specific kinases or signaling pathways.
- Combination therapies: Patents covering the use of existing drugs in combination with novel agents to enhance efficacy or overcome resistance mechanisms.
- Formulation technologies: Patents protecting specific drug delivery systems or formulations that improve bioavailability, stability, or patient compliance.
- Biologics: While AR045637 covers small molecules, the broader landscape includes patents on monoclonal antibodies and other protein-based therapeutics targeting similar pathways.
Potential Overlap and Freedom-to-Operate
A crucial aspect of the patent landscape is assessing freedom-to-operate (FTO). For any company looking to develop or market a drug related to oxindole derivatives or signal transduction inhibition in Argentina, a thorough FTO analysis is required to ensure they do not infringe existing patents. This involves:
- Infringement analysis: Comparing the company's proposed product and its manufacturing process against the claims of AR045637 and other relevant patents.
- Validity analysis: Assessing the strength and validity of existing patents. If a patent is found to be weak or invalid, it may not pose an infringement risk.
- Prior art searches: Identifying earlier inventions that might invalidate existing patents.
Given the broad nature of Formula I and the general therapeutic indications, there is a significant potential for overlap with other patented oxindole derivatives or compounds acting on similar pathways. Companies developing treatments for the same disease indications, particularly in oncology, will likely face a complex patent landscape.
Patent Strategy and Enforcement
Bayer Intellectual Property GmbH, as the patent holder, will likely employ a strategy of active patent enforcement to protect its market exclusivity. This could involve:
- Monitoring competitor activities: Regularly tracking new patent filings, product launches, and clinical trial data from competitors.
- Litigation: Pursuing legal action against entities suspected of infringing their patent rights.
- Licensing agreements: Negotiating agreements with third parties for the right to use their patented technology, either as licensor or licensee.
For AR045637, this means that any generic manufacturer seeking to enter the Argentine market after patent expiry must carefully navigate the patent landscape to ensure a smooth launch without facing immediate legal challenges.
Key Takeaways
- AR045637 protects a broad class of novel oxindole derivatives (Formula I) and their use in treating diseases linked to aberrant signal transduction, including cancers and inflammatory conditions.
- The patent grants Bayer Intellectual Property GmbH exclusive rights in Argentina until November 19, 2034.
- The patent's claims cover both the chemical compounds and their formulated pharmaceutical compositions.
- The competitive landscape for signal transduction inhibitors is intense, with numerous patents held by major pharmaceutical players.
- Thorough freedom-to-operate analysis is essential for any entity seeking to develop or market related therapeutics in Argentina to avoid infringement.
Frequently Asked Questions
-
What specific diseases are covered by the "aberrant signal transduction" umbrella in AR045637?
The patent explicitly mentions oncological diseases, including solid tumors and leukemias, and inflammatory diseases. However, the scope is broad and could encompass any condition where aberrant signal transduction plays a significant role in pathogenesis.
-
Can a generic company file an ANDA for a drug covered by AR045637 before the patent expires?
Yes, a generic company can file an Abbreviated New Drug Application (ANDA) for a drug covered by AR045637 before patent expiry. However, the ANDA approval and subsequent launch are contingent on the patent's expiration or successful legal challenges to the patent's validity or enforceability.
-
Does AR045637 cover only small molecule drugs?
Based on the description of oxindole derivatives and Formula I, AR045637 exclusively covers small molecule drugs. It does not extend to biological therapeutics like monoclonal antibodies.
-
What is the significance of the filing date versus the grant date for AR045637?
The filing date (November 19, 2014) is used to calculate the patent's term of protection, which is typically 20 years from the filing date. The grant date (November 21, 2018) signifies when the patent was officially recognized and enforceable by the Argentine patent office.
-
Are there any pending patent oppositions or legal challenges against AR045637 in Argentina?
Information regarding pending oppositions or specific legal challenges would require a dedicated search of Argentine intellectual property litigation databases and official patent office records, which is beyond the scope of this general analysis.
Citations
[1] Bayer Intellectual Property GmbH. (2018). Patente de Invención AR045637 B1. Instituto Nacional de la Propiedad Industrial (INPI), Argentina.
[2] World Intellectual Property Organization. (n.d.). Patent Law Country Profiles: Argentina. Retrieved from https://www.wipo.int/patents/en/legal_texts/patents_arg.html
